Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus

Archives of Internal Medicine

Volumn 157, Issue 11, 1997, Pages 1249-1255

  Anderson Jr , James H ^a   Brunelle, Rocco L ^a   Keohane, Patrick ^a   Koivisto, Veikko A ^b   Trautmann, Michael E ^a   Vignati, Louis ^a   DiMarchi, Richard ^a  

^a ELI LILLY AND COMPANY   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030947226     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.11.1249     Document Type: Article

References (35)

1. Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-754.
2. Alberti KGMM, Gries FA, Jervell J, Krans HMJ, for the European NIDDM Policy Group. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabet Med. 1994;11:899-909.
3. American Diabetes Association. Clinical Practice Recommendations 1995 -position statement: insulin administration. Diabetes Care. 1995;18(suppl):29-32.
4. Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992; 327:1426-1433.
5. Cerasi E, Luft R. The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. Acta Endocrinol (Copenh). 1967;55:278-304.
6. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1989;321:337-343.
7. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 1993;16:642-652.
8. Gerstein HC, Yusuf S. Dysglycemia and cardiovascular disease. Lancet. 1996; 347:949-950.
9. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin-dependent diabetes followed for three years. BMJ. 1995;310:83-88.
10. Ceriello A, Taboga C, Tonutti L, et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia. 1996;39:469-473.
11. DiMarchi RD, Chance R, Long HB, Shields JE, Slieker LJ. Preparation of insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm Res. 1994;41(suppl):93-96.
12. Howey DC, Bowsher RR, Brunelle R, Woodworth JR. (Lys[B28], Pro[B29])-human insulin: a rapidly absorbed analogue of human insulin. Diabetes. 1994; 43:396-402.
13. Howey DC, Bowsher RR, Brunelle R, et al. (Lys[B28], Pro[B29])-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther. 1995;58:459-469.
14. Tuominen JA, Karonen S-L, Melamies L, Bolli G, Koivisto VA. Exercise-induced hypoglycemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia. 1995;38:106-111.
15. WHO Expert Committee on Diabetes Mellitus: 2nd Report. Geneva, Switzerland: World Health Organization; 1980. Technical report series 646.
16. Hoffmeister H, Junge B. Über die Haltbarkeit von Serumbestandteilen and die Zuverlassigkeit ihrer Bestimmung im Autoanalyzer SMA 12-30-Survey. Z Klin Chem Klin Biochem. 1970;8:613-617.
17. 1c by high performance cation exchange chromatography. Clin Chem. 1980;26:3-7.
18. 2+ dextran sulphate in its enzymatic measurement. Clin Chem. 1978;24:931-933.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
20. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics. 1972;28:577-584.
21. Taulbee JD. A note on the use of nonparametric methods in the statistical analysis of the two-period changeover design. Biometrics. 1982;38:1053-1055.
22. Nagelkerke NJD, Hart AAM, Oosting J. The two-period binary response crossover trial. Biomed J. 1986;28:863-869.
23. Slieker LJ, Brooke GS, Chance RE, et al. Insulin and IGF-I analogs: novel approaches to improved insulin pharmacokinetics. In: Leroith D, Raizala MK, eds. Current Directions in Insulin-like Growth Factor Research. New York, NY: Plenum Publishing Corp; 1994:25-32.
24. Fineberg SE, Fineberg NS, Anderson JH, Birkett M, Gibson RG, Huferd S. Comparative immunogenecity of LysPro (B28, B29) human insulin analog between type I and type II patients. Diabetologia. 1994;37(suppl):A168.
25. Fineberg SE, Fineberg NS, Anderson JH, Birkett M. Insulin immune response to lyspro human insulin therapy in insulin naive type I and type II patients. Diabetologia. 1995;38(suppl):A4.
26. Buelke-Sam J, Byrd RA, Hoyt JA, Zimmerman JL. A reproductive and developmental toxicity study in CD rats of LY275585, (Lys[B28], Pro[B29])-human insulin. J Am Coll Toxicol. 1994;13:247-260.
27. Lean MEJ, Ng LL, Tennison BR. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. BMJ. 1985;290:105-108.
28. Jörgensen LN, Nielsen FS. Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen: a questionnaire study. Diabetologia. 1990; 33(suppl):A116.
29. Kinmonth AL, Baum JD. Timing of pre-breakfast insulin injection and post-prandial metabolic control in diabetic children. BMJ. 1980;280:604-606.
30. Anderson JH Jr, Brunelle RL, DiMarchi R, et al, for the Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients during insulin analog treatment. Diabetes. 1997;46:265-270.
31. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care. 1990;13: 631-654.
32. Janka HU, Ziegler AG, Standl E, Mehnert H. Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. Diabetes Metab. 1987;13:359-364.
33. Rönnemaa T, Laakso M, Puukka P, Kallio V, Pyörälä K. Atherosclerotic vascular disease in middle-aged, insulin-treated, diabetic patients. Arteriosclerosis. 1988;8:237-244.
34. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37: 1495-1507.
35. Fussgänger R, Jehle P, Kunze U, Dolderer M, Koop I. Improved insulin binding to monocytes of IDDM patients intensively treated with lys (B28), pro (B29) human insulin. Diabetologia. 1994;37(suppl):A167.